Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that the U.S. Food and Drug Administration (FDA) has approved RELISTOR(TM) (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-induced constipation (OIC) in patients
Amneal Pharmaceuticals has announced the execution of an asset purchase agreement for Amneal's wholly-owned subsidiary, Amneal Pharmaceuticals of New York, to acquire the assets, facilities and business of Interpharm.
Aeolus Pharmaceuticals has reported that researchers from the National Jewish Research and Medical Center and the University of Colorado have completed a series of studies demonstrating that AEOL 10150 provides statistically significant protection of the lungs and skin in the
ProMetic Life Sciences has said that its oral PBI-1402 has demonstrated significant activity in patients with chemotherapy-induced anemia, and reduces the need for red blood cell transfusion.
Abraxis BioScience has reported positive Phase I trial data, which shows clinical benefit of Abraxane for injectable suspension in combination with Gemzar in advanced pancreatic patients.
Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has filed an abbreviated new drug application with the FDA seeking approval to market its fentanyl buccal tablets C-II product prior to the expiration of patents owned by Cephalon.
China Sky One Medical, a pharmaceutical company for external use over-the-counter drugs in the People's Republic of China has acquired Heilongjiang Haina Pharmaceutical.
The Alliance for Better Bone Health, a collaboration between Procter & Gamble Pharmaceuticals and Sanofi-Aventis US, has announced that FDA has approved a new once-a-month dose of Actonel tablets for the treatment and prevention of postmenopausal osteoporosis.
Wyeth Pharmaceuticals, a division of Wyeth and Progenics Pharmaceuticals have received a positive opinion for Relistor subcutaneous injection from the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency.
CV Therapeutics has announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of ranolazine in the EU for the treatment of chronic angina.
Nventa Biopharmaceuticals has announced the completion of the safety and tolerability assessment of the fourth and final cohort of patients in its Phase I clinical trial of HspE7, its lead therapeutic candidate, in women with cervical intraepithelial neoplasia.
Lannett has received approval from the FDA for its abbreviated new drug application for dipyridamole tablets USP, 25mg, 50mg, and 75mg, the generic equivalent of Persantine tablets manufactured by Boehringer Ingelheim.
Genentech has announced that the California Supreme Court has overturned the award of $200 million in punitive damages resulting from a contract dispute brought by the City of Hope National Medical Center.
Stem Cell Therapeutics has announced that FDA has allowed its investigational new drug application to begin a double-blind, randomized, placebo-controlled Phase IIb clinical trial of its lead program, NTx-265, for the treatment of acute ischemic stroke.
SurModics has announced that its Brookwood Pharmaceuticals subsidiary, located in Birmingham, Alabama, has acquired an additional facility in the Birmingham area.
